The FDA has granted bardoxolone methyl (bardoxolone; Reata Pharmaceuticals) Orphan Drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Nearly half of patients with autosomal dominant polycystic kidney disease receive at least 1 CT scan over 2 years, study finds.
Investigators found a U-shaped curve of mortality against ferritin/TSAT levels in patients without autosomal dominant polycystic kidney disease, but not in those with the disease.
In a phase 2 trial that enrolled 31 patients with autosomal dominant polycystic kidney disease, treatment with bardoxolone resulted in a significant increase in kidney function.
